Cristal Therapeutics announces formation of Scientific Advisory Board

Cristal Therapeutics has announced the appointments of Professor Dr Rob Liskamp, Professor Dr Twan Lammers, Professor Dr Alberto Gabizon, Dr Maninder Hora and Dr William Zamboni to its new Scientific Advisory Board.

Cristal Therapeutics is a privately-held biopharmaceutical company developing novel therapeutics against cancer and other diseases, such as chronic inflammatory disorders, by using its patented CriPec® platform.

Scientific Advisory Board represent a major information resource for Cristal Therapeutics

Prof. Dr Rob Liskamp is professor and chair of Chemical Biology and Medicinal Chemistry at the University of Glasgow, while maintaining a part-time appointment at Utrecht University as professor of Molecular Medicinal Chemistry.

Prof. Dr Twan Lammers is professor and head of the department of Nanomedicine and Theranostics at the Institute for Experimental Molecular Imaging at RWTH Aachen University and at the Helmholtz Institute for Biomedical Engineering. Since 2012, he has also been appointed at the Department of Targeted Therapeutics at the University of Twente.

Prof. Dr Alberto Gabizon, is Professor of Oncology (Shaare Zedek Medical Center, The Hebrew University of Jerusalem), President and founder of LipoMedix Pharmaceuticals and a renowned scientist and clinician in the field of nanomedicine and cancer therapy.

Dr Maninder Hora, is Senior Vice President, Pharmaceutical Development & Manufacturing Operations of Nektar Therapeutics, headquartered in San Francisco, California,  and Board Member of Nektar India, located in Hyderabad.

Dr William Zamboni is associate professor at the Eshelman School of Pharmacy and Lineberger Comprehensive Cancer Center at the University of North Carolina in Chapel Hill. He is also the Director of the Translational Oncology and Nanoparticle Drug Development Initiative Lab.

“We welcome the unparalleled clinical and research experience that professors Liskamp, Lammers, Gabizon, Hora and Zamboni bring to the Cristal Therapeutics’ Scientific Advisory Board. Together they represent a major information resource for Cristal Therapeutics, that will play an important role in both our development programmes and our plans related to product commercialisation as well as licensing and partnership opportunities,” said Cristianne Rijcken, CSO of Cristal Therapeutics.